Immunomedics, Inc. announced that its Board of Directors has voted to appoint Michael Pehl as President and Chief Executive Officer, effective December 7, 2017. He has also been appointed to the Board, effective as of the commencement date of Mr. Pehl's employment. The company also announced that Brendan Delaney has been appointed Chief Commercial Officer, effective as of November 10, 2017.

In his role as CCO at the company, Brendan will be responsible for building out the Company's commercialization team including sales, marketing, market access and pricing. He will report directly to Michael Pehl. Michael Garone, current Chief Financial Officer and Interim CEO, will resume his role as CFO.

Mr. Pehl brings to Immunomedics a history of success as a global pharmaceutical leader. Most recently, he served as President, Hematology & Oncology, at Celgene Corporation (Celgene), and prior to that was the company's Head of Global Marketing, Head of Hematology Europe and the first General Manager of Celgene in Germany. Brendan was most recently Vice President, U.S. Commercial Hematology Oncology at Celgene.